* Note: Prices are in Million (M) USD.
Description:
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $101 M
Debt : $59 M
EBITDA : $8 M
Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 23.62
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-17 M
Average Revenue: $61 M
Revenue Converted To Free Cash Flow (%): -28%
Avg Free Cash Flow Growth Per Year (Last 5 Years): -42.33%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $211 M
Revenue 4 Years Ago (2020-12-31): $0 M
Last 5 Years Average Revenue Growth: 0%
Since Revenue Growth is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $39 M
Share Count 5 Years Ago (2020-12-31): $31 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $0.00
Trailing 12-Month Earnings Per Share (EPS): $0.51
Average Earnings Per Share (EPS): $0.26
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -11%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $6
52-Week Low: $6
Threshold Price (15% Above 52-Week Low): $7
Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $252 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based the market cap, we recommend do not exceed 0.5% exposure of Total Portfolio.
Value-Trade has assigned 19 points to above Entrada Therapeutics Inc (TRDA) stock.
Last 1 Years Avg PE 9.05, Fair Value PE 20, Industry Based PE 20. Based on these 3 values, average assigned is 16.35.
Value-Trades has assined P/E value 16.35. Since an average (Current Year EPS + Next Year EPS) earning per share is $0.26.
The fair value of Entrada Therapeutics Inc (TRDA) stock should be (16.35 x $0.26) = $4.25
